Docoh
Loading...

ALXN Alexion Pharmaceuticals

GRANT
Utility
Methods for treating hypophosphatasia in children
20 Jul 21
The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child having HPP) exhibiting physical impairments, disability in activities of daily living (ADL), pain, and/or delayed motor development by administering a soluble alkaline phosphatase (sALP) to the patient.
Kenji Fujita, Dawn Phillips
Filed: 1 Sep 16
APP
Utility
Dosage and Administration of ANTI-C5 Antibodies for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) In Pediatric Patients
15 Jul 21
Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in pediatric patients using an anti-C5 antibody, or antigen binding fragment thereof.
Lori PAYTON, Scott T. ROTTINGHAUS, Rajendra PRADHAN, Stephan ORTIZ, Masayo OGAWA, Xiang GAO
Filed: 29 May 19
APP
Utility
Compositions Comprising an ANTI-C5 Antibody
15 Jul 21
The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.
Yi WANG
Filed: 19 Jan 21
APP
Utility
Methods for Treating Diseases Associated with Ciliopathies
24 Jun 21
Methods of treating a ciliopathy-associated disease are disclosed, including administering to a subject in need thereof an effective amount of a compound that targets at least one G-protein coupled receptor.
Sophie SAUNIER, Luis BRISENO-ROA, Soraya SIN-MONNOT, Jean-philippe ANNEREAU, Marion DELOUS, Hugo GARCIA, Guillermo DEL ANGEL, Flora LEGENDRE
Filed: 12 Oct 18
APP
Utility
Efficacy of an ANTI-C5 Antibody In the Prevention of Antibody Mediated Rejection In Sensitized Recipients of Kidney Transplant
24 Jun 21
A method for preventing AMR in a human kidney transplant recipient is provided.
Herman GRIFFIN, Xiang GAO, Rebecca VELEZ, Wei-Jian PAN
Filed: 27 Oct 20
APP
Utility
Biodegradable Activated Polymers for Therapeutic Delivery
24 Jun 21
Activated polymers comprising one or more backbone ester(s) are disclosed.
Christopher J. CHENG, W. Mark SALTZMAN, Junwei ZHANG
Filed: 28 Feb 17
APP
Utility
Bis-Choline Tetrathiomolybdate for Treating Wilson Disease
17 Jun 21
Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided.
Carl BJARTMAR, Karl-Heinz WEISS, Michael SCHILSKY, Frederick ASKARI, Anna CZLONKOWSKA, Peter FERENCI, Peter HEDERA, Aftab ALA
Filed: 22 Feb 21
APP
Utility
Alkaline Phosphatase Polypeptides and Methods of Use Thereof
10 Jun 21
Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof.
Walter C. VOEGTLI, Michael BARANELLO, Keith BOUCHARD
Filed: 9 Dec 20
APP
Utility
Lysosomal Storage Disease Enzymes
10 Jun 21
The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
Anthony QUINN, Alex J. HARVEY
Filed: 9 Nov 20
GRANT
Utility
Lyophilized formulations for factor Xa antidote
8 Jun 21
The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes.
Juan Wang, Gregory A. Sacha, Phuong M. Nguyen
Filed: 8 Jun 20
GRANT
Utility
Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
8 Jun 21
This invention provides, inter alia, a complement-inhibitor-based treatment plan coupled with a risk evaluation and management strategy (“REMS”) and a safety support program (“SSP”) for reinforcing the REMS.
Leonard Bell, Camille Bedrosian
Filed: 13 Nov 15
APP
Utility
Methods of Treating Neurofibromatosis Type 1 and Related Conditions with Alkaline Phosphatase
3 Jun 21
The disclosure features methods for treating at least one symptom of neurofibromatosis type 1, treating at least one symptom of dystrophic scoliosis, or inducing bone healing by administering a soluble alkaline phosphatase (sALP) to the patient.
Anna PETRYK
Filed: 9 Aug 19
APP
Utility
Bis-Choline Tetrathiomolybdate for Treating Wilson Disease
13 May 21
Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided.
Carl BJARTMAR, Karl-Heinz WEISS, Michael SCHILSKY, Frederick ASKARI, Anna CZLONKOWSKA, Peter FERENCI, Peter HEDERA, Aftab ALA
Filed: 4 Dec 18
APP
Utility
Solid Forms of Cerdulatinib
6 May 21
Forms of cerdulatinib and salts or co-crystals thereof were prepared and characterized in the solid state.
Anjali Pandey, Julian Scott Northen, Philippe Fernandes, Ying Chen, Yuelie Lu, Sami Karaborni, Gus Kodersha
Filed: 16 Nov 20
APP
Utility
Methods of Producing ANTI-C5 Antibodies
29 Apr 21
The present application relates to a method of producing an anti-C5 antibody (ravulizumab). wherein the method comprises: —culturing mammalian cells comprising a nucleic acid encoding the anti-C5 antibody in a cell culture production medium—Performing two or more steps selected from the group consisting of: a recovery step; purification by Protein A affinity chromatography, a low pH viral inactivation step; Purification by cation exchange chromatography; Purification by anion exchange chromatography; a virus reduction filtration step; and a concentration and diafiltration step
Hunter F. MALANSON, Kyle A. ZINGARO, Anjil GIRI, Justin WEAVER, Abraham FRIEDMAN, Jeffrey William HUNTER, Saranya SIVANANDAM, Jeffrey ZUGATES, Rahul GODAWAT
Filed: 27 Jun 19
GRANT
Utility
Method of producing alkaline phosphatase
27 Apr 21
The disclosure provides a method of producing recombinant alkaline phosphatase comprising: (i) culturing an alkaline phosphatase in a recombinant cell culture; (ii) obtaining a preparation of recombinant alkaline phosphatase from the cell culture; and (iii) minimizing in the preparation a concentration of at least one metal ion selected from the group consisting of: Nickel (Ni), Cobalt (Co), Copper (Cu), Manganese (Mn), Chromium (Cr), and Molybdenum (Mo).
Saravanamoorthy Rajendran, Rachael Alford, Sean Gallagher, Anne Kantardjieff, Jared Davis
Filed: 6 Jun 17
APP
Utility
Bis-Choline Tetrathiomolybdate for Treating Wilson Disease
1 Apr 21
Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided.
Carl BJARTMAR, Karl-Heinz WEISS, Michael SCHILSKY, Frederick ASKARI, Anna CZLONKOWSKA, Peter FERENCI, Peter HEDERA, Aftab ALA
Filed: 19 Aug 20
APP
Utility
Crystalline Particles of Bis-Choline Tetrathiomolybdate
1 Apr 21
Novel crystalline particles, methods for manufacture of crystalline particles, and solid unit dosage forms, particularly tablets or capsules, of bis-choline tetrathiomolybdate are provided.
Lars OLSSON, Viveca T. OLTNER
Filed: 6 Feb 19
APP
Utility
Liquid Formulations of ANTI-CD200 Antibodies
25 Mar 21
The present disclosure provides stable liquid pharmaceutical formulations comprising anti-CD200 antibodies or antigen-binding fragments thereof, and articles of manufacture and kits containing the formulations.
Dino MIANO, Bruce MASON
Filed: 18 Dec 18
GRANT
Utility
Antidotes for factor Xa inhibitors and methods of using the same
23 Mar 21
The present invention relates antidotes to anticoagulants targeting factor Xa.
Uma Sinha, Genmin Lu, Pamela B. Conley
Filed: 17 Jan 19
Patents are sorted by USPTO publication date, most recent first